Company news
Editas Medicine, Inc. (NASDAQ:EDIT) news
Editas Medicine, Inc. news releases on 6ix. Latest, Sep 8, 2026: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Press releases & updates
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
September 8, 2026
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
August 5, 2026
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
August 4, 2026
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
May 28, 2026
Editas Medicine Announces Proposed Public Offering
May 26, 2026
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
May 26, 2026
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
May 13, 2026
Editas Medicine Announces First Quarter 2026 Results and Business Updates
May 5, 2026
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
April 26, 2026
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
March 26, 2026
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
March 8, 2026
Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies
November 20, 2025
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
November 9, 2025
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
November 2, 2025
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
October 8, 2025
Scientific Equipment Goes to Auction in Tiger Group and EquipNet Sale on Oct. 16
October 8, 2025
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
October 5, 2025
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
September 1, 2025
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
August 27, 2025
Editas Medicine to Participate in Upcoming Investor Conferences
August 26, 2025
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
August 11, 2025
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
June 11, 2025
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
May 13, 2025
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
May 13, 2025
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
May 12, 2025
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
May 11, 2025
Editas Medicine Announces First Quarter 2025 Results and Business Updates
May 11, 2025
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
May 4, 2025
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
April 27, 2025
Editas Medicine Announces Chief Financial Officer Transition
March 19, 2025
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
March 4, 2025
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
February 23, 2025
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
January 12, 2025
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 5, 2025
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
December 11, 2024
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
December 8, 2024
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
November 3, 2024
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
October 21, 2024
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
October 20, 2024
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
October 17, 2024
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
October 2, 2024
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
August 6, 2024
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
July 30, 2024
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
June 13, 2024
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
June 13, 2024
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
May 13, 2024
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
May 9, 2024
Editas Medicine Announces First Quarter 2024 Results and Business Updates
May 7, 2024
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
May 1, 2024
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
April 30, 2024